Instead, the other biologic drugs approved by the EMA are indicated for specific Type 2 severe asthma phenotypes (e.g. “Allergic” for anti-IgE or “Eosinophilic” for anti-IL5) [32–36]. This evidence concerns the gene IL5 and asthma.